Medidata eyes development in China with cloud and AI services
Medidata, a US-based cloud and AI service provider in life science industry, has high expectations for China and especially Shanghai.
At present, Medidata has 1,300 customers in their clinical trial studies and touches lives of more than 4.8 million patients globally. In Asia Pacific, it has 312 customers with a growing Chinese customer base, which accounts for almost one-third of all customers.
China has a great potential for Medidata with an aging population and an expanding middle class. Shanghai has a "bio-medicine valley" for life science research and new drug development, which has gathered many pharmaceutical firms. Some of which have global expansion ambitions, said Jim Xu, general manager of Medidata China.
Besides Shanghai, Medidata has long-term cooperation with clients in Suzhou and Nanjing, Xu added.
With cloud and new AI services, Medidata helps clients transform clinical research in greater efficiencies, smarter treatments and healthier people. It helps Chinese life science companies improve new drug test and application process and ensure them meet global standards.
China, as well as the Asia-Pacific region, is regarded as fertile ground for technology firms working with drug developers to provide latest technologies like AI. It’s a booming realm due to aging populations, large investment inflows, unmet medical needs, regulatory reforms and local pharmaceutical companies with global expansion ambitions, analysts said.